title: Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
abstract: A dramatic increase in the incidence of esophageal adenocarcinoma has occurred among men in the United States over the last two decades. The underlying reasons remain largely unknown, although the increasing prevalence of obesity likely plays a role. Most adenocarcinomas arise in a metaplastic epithelium termed Barrett's esophagus (BE) that develops in approximately 10% of persons who have chronic gastroesophageal reflux. Persons with BE are at high risk (0.5-1.0%/year) of progressing to cancer. In a cross-sectional study of 429 persons with BE, we evaluated the associations between increased body mass index, anthropometric measures, cigarette smoking, use of nonsteroidal anti-inflammatory drugs (NSAIDs) and markers of increased risk, including aneuploidy, increased 4N fraction, loss of heterozygosity (LOH) of 17p and 9p alleles, and high-grade dysplasia (HGD). In logistic regression models adjusting for age, gender, NSAID use, and cigarette smoking, increasing waist:hip ratio was related to increasing risk of aneuploidy (trend P = 0.01), 17p LOH (trend P = 0.005), and 9p LOH (trend P = 0.007). The odds ratios comparing highest to lowest quartiles were 4.3 [95% confidence interval (CI), 1.2-15.6] for aneuploidy, 3.9 (95% CI, 1.3-11.4) for 17p LOH, and 2.7 (95% CI, 1.2-6.3) for 9p LOH. A nonsignificant trend was also observed for increased 4N fraction, whereas little association was found for HGD. Similar patterns of risk were noted for other anthropometric measures such as waist:thigh and abdomen:thigh ratios. There was no evidence that elevated body mass index increased risk of any of the biomarkers. Suggestive evidence also was found for a protective effect of NSAID use. The odds ratios for current users, compared with those who never used NSAIDs regularly, were 0.6 (95% CI, 0.3-1.4) for increased 4N, 0.6 (95% CI, 0.3-1.3) for aneuploidy, 0.3 (95% CI, 0.1-0.7) for 17p LOH, and 0.7 (95% CI, 0.4-1.2) for HGD. There was no association between NSAID use and risk of 9p LOH. We conclude that an abdominal distribution of body fat, which is more common in men and is termed male-pattern obesity, may be a strong predictor of risk of neoplastic progression among persons with BE and may account in part for the male predominance of BE and esophageal adenocarcinoma. We also conclude that NSAID use may reduce the risk of progression to cancer in this population. Prospective studies are needed to confirm these results.
authors.affiliation: Program in Epidemiology [T. L. V.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. tvaughan@u.washington.edu
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Vaughan
authors.forename: Alan R
authors.initials: AR
authors.lastname: Kristal
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Blount
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Levine
authors.forename: Patricia C
authors.initials: PC
authors.lastname: Galipeau
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Prevo
authors.forename: Carissa A
authors.initials: CA
authors.lastname: Sanchez
authors.forename: Peter S
authors.initials: PS
authors.lastname: Rabinovitch
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Reid
mesh_terms: D000328:Adult; D000368:Aged; D000782:Aneuploidy; D000886:Anthropometry; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001471:Barrett Esophagus / Q000209:etiology* / Q000235:genetics*; D015992:Body Mass Index; D002471:Cell Transformation, Neoplastic; D004938:Esophageal Neoplasms / Q000209:etiology / Q000235:genetics*; D005260:Female; D005434:Flow Cytometry; D005819:Genetic Markers; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D016017:Odds Ratio; D012044:Regression Analysis; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005819:Genetic Markers